Suzanne V Arnold1, John A Spertus2, Kasia J Lipska3, David E Lanfear4, Fengming Tang5, Anna Grodzinsky2, Darren K McGuire6, M Odette Gore7, Abhinav Goyal8, Thomas M Maddox9, Mikhail Kosiborod2. 1. Saint Luke's Mid America Heart Institute, Kansas City, MO; University of Missouri-Kansas City, Kansas City, MO. Electronic address: suz.v.arnold@gmail.com. 2. Saint Luke's Mid America Heart Institute, Kansas City, MO; University of Missouri-Kansas City, Kansas City, MO. 3. Yale School of Medicine, New Haven, CT. 4. Henry Ford Hospital, Detroit, MI. 5. Saint Luke's Mid America Heart Institute, Kansas City, MO. 6. University of Texas Southwestern Medical Center, Dallas, TX. 7. University of Colorado School of Medicine, Denver, CO. 8. Emory School of Medicine, Atlanta, GA. 9. University of Colorado School of Medicine, Denver, CO; VA Eastern Colorado Health Care System, Denver, CO.
Abstract
BACKGROUND: Discharge β-blocker prescription after myocardial infarction (MI) is recommended for all eligible patients. Numerous β-blocker choices are presently available with variable glycometabolic effects, which could be an important consideration in patients with diabetes mellitus (DM). Whether patients with DM preferentially receive β-blockers with favorable metabolic effects after MI and if this choice is associated with better glycemic control postdischarge is unknown. METHODS: Among patients from 24 US hospitals enrolled in an MI registry (2005-2008), we investigated the frequency of "DM-friendly" β-blocker prescription at discharge by DM status. β-Blockers were classified as DM-friendly (eg, carvedilol and labetalol) or non-DM-friendly (eg, metoprolol and atenolol), based on their effects on glycemic control. Hierarchical, multivariable logistic regression examined the association of DM with DM-friendly β-blocker use. Among DM patients, we examined the association of DM-friendly β-blockers with worsened glycemic control at 6 months after MI. RESULTS: Of 4,031 MI patients, 1,382 (34%) had DM. β-Blockers were prescribed at discharge in 93% of patients. Diabetes mellitus-friendly β-blocker use was low regardless of DM status, although patients with DM were more likely to be discharged on a DM-friendly β-blocker compared with patients without DM (13.5% vs 10.3%, P = .003), an association that remained after multivariable adjustment (odds ratio 1.41, 95% CI 1.13-1.77). There was a trend toward a lower risk of worsened glucose control at 6 months in DM patients prescribed DM-friendly versus non-DM-friendly β-blockers (Relative Risk 0.80, 95% CI 0.60-1.08). CONCLUSION: Most DM patients were prescribed non-DM-friendly β-blockers-a practice that was associated with a trend toward worse glycemic control postdischarge. Although in need of further confirmation in larger studies, our findings highlight an opportunity to improve current practices of β-blockers use in patients with DM.
BACKGROUND: Discharge β-blocker prescription after myocardial infarction (MI) is recommended for all eligible patients. Numerous β-blocker choices are presently available with variable glycometabolic effects, which could be an important consideration in patients with diabetes mellitus (DM). Whether patients with DM preferentially receive β-blockers with favorable metabolic effects after MI and if this choice is associated with better glycemic control postdischarge is unknown. METHODS: Among patients from 24 US hospitals enrolled in an MI registry (2005-2008), we investigated the frequency of "DM-friendly" β-blocker prescription at discharge by DM status. β-Blockers were classified as DM-friendly (eg, carvedilol and labetalol) or non-DM-friendly (eg, metoprolol and atenolol), based on their effects on glycemic control. Hierarchical, multivariable logistic regression examined the association of DM with DM-friendly β-blocker use. Among DMpatients, we examined the association of DM-friendly β-blockers with worsened glycemic control at 6 months after MI. RESULTS: Of 4,031 MI patients, 1,382 (34%) had DM. β-Blockers were prescribed at discharge in 93% of patients. Diabetes mellitus-friendly β-blocker use was low regardless of DM status, although patients with DM were more likely to be discharged on a DM-friendly β-blocker compared with patients without DM (13.5% vs 10.3%, P = .003), an association that remained after multivariable adjustment (odds ratio 1.41, 95% CI 1.13-1.77). There was a trend toward a lower risk of worsened glucose control at 6 months in DMpatients prescribed DM-friendly versus non-DM-friendly β-blockers (Relative Risk 0.80, 95% CI 0.60-1.08). CONCLUSION: Most DMpatients were prescribed non-DM-friendly β-blockers-a practice that was associated with a trend toward worse glycemic control postdischarge. Although in need of further confirmation in larger studies, our findings highlight an opportunity to improve current practices of β-blockers use in patients with DM.
Authors: Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel Journal: Circulation Date: 2007-08-06 Impact factor: 29.690
Authors: Suzanne V Arnold; Paul S Chan; Philip G Jones; Carole Decker; Donna M Buchanan; Harlan M Krumholz; P Michael Ho; John A Spertus Journal: Circ Cardiovasc Qual Outcomes Date: 2011-07
Authors: Christian Torp-Pedersen; Marco Metra; Andrew Charlesworth; Phillip Spark; Mary Ann Lukas; Philip A Poole-Wilson; Karl Swedberg; John G F Cleland; Andrea Di Lenarda; Willem J Remme; Armin Scherhag Journal: Heart Date: 2007-01-19 Impact factor: 5.994
Authors: Joshua M Stolker; John A Spertus; Darren K McGuire; Marcus Lind; Fengming Tang; Philip G Jones; Silvio E Inzucchi; Saif S Rathore; Thomas M Maddox; Frederick A Masoudi; Mikhail Kosiborod Journal: Diabetes Care Date: 2012-03-12 Impact factor: 19.112
Authors: Suzanne V Arnold; Joshua M Stolker; Kasia J Lipska; Philip G Jones; John A Spertus; Darren K McGuire; Silvio E Inzucchi; Abhinav Goyal; Thomas M Maddox; Marcus Lind; Divya Gumber; Supriya Shore; Mikhail Kosiborod Journal: Circ Cardiovasc Qual Outcomes Date: 2015-04-21
Authors: Andrew R Zullo; Michelle Hersey; Yoojin Lee; Sadia Sharmin; Elliott Bosco; Lori A Daiello; Nishant R Shah; Vincent Mor; W John Boscardin; Christine M Berard-Collins; David D Dore; Michael A Steinman Journal: Diabetes Obes Metab Date: 2018-07-22 Impact factor: 6.577